Boston Scientific Corporation (BSX) Income Statement

The steady step-down across the last five quarters suggests the earlier high-teens to low-20s expansion was partly supported by acquisition contribution and lapping of easier comparisons rather than purely organic momentum. The 2026Q3 reading of 1.4% is a sharp break that may indicate either timing effects in procedural volumes or a genuine slowdown in core franchises, and investors should monitor whether subsequent quarters confirm a durable reset. Without guidance commentary in the latest report, the market has limited anchors for judging whether this deceleration is transitory.

The wide quarterly swing in gross margin, particularly the 15.9-point range between the 2024Q4 trough and the 2025Q4 peak, suggests that product mix, inventory adjustments, or one-time items are influencing reported gross profit more than a stable pricing structure would imply. The current 66.7% level sits in line with Stryker and Medtronic, which indicates pricing power is solid but not exceptional relative to the most focused structural heart competitor. Investors should treat the 2026Q3 compression from 74.5% as a signal to examine whether GPO pricing pressure or EP competition is beginning to affect unit economics.

The fixed-cost base, dominated by the clinical sales organization and SG&A, appears to have absorbed the revenue slowdown without corresponding cost flexibility, which is the opposite of the operating leverage the company previously demonstrated. Operating income dropping from $1.2B to $979M in a single quarter suggests the margin compression is more than a rounding effect. This pattern may indicate that the earlier expansion relied partly on revenue momentum rather than sustained cost discipline, a conclusion that warrants further investigation as segment-level costs become available.